Transcript Slide 1

Day1 Plenary Session
Lecture 1: Propagation of the neurodegenerative process
in PD and the Prion-like hypothesis
Lecture 2: Can the interaction between genetics, environment, and
behavior be a key determinant of PD expression
Lecture 3: What epidemiological and preclinical studies teach us
about inflammation and PD
Lecture 4: Developing new treatments founded on the basic science of PD
Special Lecture 1: The Life and Times of James Parkinson
Special Lecture 2: The Glory of Canadian Sciences and Parkinson's Disease
Mo
Simon
Werner
L1
X
X
L2
X
X
X
L3
X
X
L4
X
X
X
SpL1 SpL2
X
Day 2 Plenary Session
Lecture 1: The spectrum of non-motor symptoms in PD
Lecture 2: Dementia and psychiatric manifestations in PD
Lecture 3: Contribution of functional neuroimaging to the
understanding of non-motor manifestations of PD
Lecture 4: The impact of other medical conditions on the course of PD
WPC James Parkinson Lecture: Past, Present and Future of Parkinson’s
Disease
Mo
Simon
Werner
L1
X
X
L2
X
X
X
L3
X
X
L4
X
X
X
JPL
X
Day 3 Plenary Session
Lecture 1: Cell and gene-based technologies for restorative and
neuroprotective therapies
Lecture 2: Exercise, diet, and other lifestyle activities as treatments for
Parkinson disease
Lecture 3: Empowered patients and how they can help improve healthcare
Lecture 4: Roles for healthcare professionals: multidisciplinary care
for Parkinson disease.
Special Lecture: Living Positively After a Diagnosis of Parkinson's
Mo
Simon
Werner
L1
X
X
X
L2
X
X
L3
X
X
L4
X
SpL
X
X
X
Day 1 Parallel Session I
Parallel Session: New genes and risk factors of PD
Lecture 1: New PD genes and rare variants
Lecture 2: Risk factors for sporadic PD
Lecture 3: Genetics and gene environment interactions
Parallel Session: Protein misfolding as a key pathogenic event
Lecture 1: Alpha-synuclein conformation and neurodegeneration
Lecture 2: Protein misfolding in neurodegenerative diseases
Lecture 3: Link between lysosomal function and neurodegeneration in PD
Parallel Session: Role of functional imaging modalities in the diagnosis and
management of PD
Lecture 1: Structural imaging for PD: MRI and transcranial sonography (TCS)
Lecture 2: Neurochemical imaging
Lecture 3: Functional connectivity
Parallel Session: Non-dopaminergic systems in PD: Anatomy, Biochemistry, and Pathology
Lecture 1: Role of noradrenaline and serotonin systems for the development of nonmotor symptoms
Lecture 2: Impact of cholinergic dysfunction on the development of non-motor symptoms
Lecture 3: Role of non-dopaminergic systems in the development of L-DOPA-induced
dyskinesias
Day 1 Parallel Session I
Workshop 1: Why supporting research is crucial: from government to
private funding agencies
Workshop 2: Mitochondrial defect in PD: myth or reality?
Workshop 3: Sexual issues in Parkinson's disease: assessment and intervention
Workshop 4: Quality of life and comfort in the late stages of Parkinson's disease
L1
Mo
Simon
Werner
L2
L3
L1
L2
L3
L1
L2
L3
L1
L2
L3
X
X
X
W1 W2 W3 W4
X
X
X
Day 1 Parallel Session II
Parallel Session: Quality of life in Parkinson’s disease: several important determinants
Lecture 1: Practical solutions to driving, early job loss, and relationship issues
Lecture 2: Psychological solutions to dealing with pity, dignity, sense of worth and communication
Lecture 3: Physical solutions to coping with pain, motor/non-motor, cognition, mood, and behavior
Parallel Session: How Parkinson’s affects attention and memory
Lecture 1: Memory and attention issues in Parkinson’s disease—clinical characteristics
and mechanisms
Lecture 2: Clinical Assessment of Cognition in PD
Lecture 3: Practical management of cognitive deficits in Parkinson's
disease; what can occupational therapists offer?
Parallel Session: Experimental models of non-motor manifestations of PD
Lecture 1: Animal models of hyper dopaminergic behavior in Parkinson’s disease
Lecture 2: Animal models of sleep disorders in Parkinson’s disease
Lecture 3: Animal models of gastrointestinal dysfunction in Parkinson’s disease
Parallel Session: Optogenetic tools to study PD pathophysiology
Lecture 1: Optical Neural Engineering
Lecture 2: Regulation of Parkinsonian motor behaviors by optogenetic control of
basal ganglia circuitry
Lecture 3: Optical Interrogation of the dopaminergic systems
Day 1 Parallel Session II
Workshop 1: Everything you always wanted to know about genetics
and that you never dared to ask
Workshop 2: How researchers and people with Parkinson’s can advance
clinical trials together
Workshop 3: How drugs make it to your cabinet
Workshop 4: Music, art, creativity and Parkinson's
L1
Mo
Simon X
Werner
L2
L3
X
X
L1
X
L2
X
L3
X
X
X
X
L1
L2
L3
L1
L2
L3
W1 W2 W3 W4
X
X
X
Day 2 Parallel Session I
Parallel Session: PD or not PD - that is the question: Is it time to redefine/reclassify Parkinson’s
disease?
Lecture 1: Current definitions and diagnostic criteria: reasons for redefining the disorder.
Lecture 2: The challenge of "prodromal" Parkinson's disease
Lecture 3: Redefining Parkinson's disease: possible approaches to
developing new diagnostic criteria
Parallel Session: Hallucinations and related phenomena in PD
Lecture 1: Prototypical and less common hallucinations
Lecture 2: Where is the nucleus hallucinatorius and how it gets stimulated?
Lecture 3: Management of hallucinations and related symptoms
Parallel Session: Mitochondrial quality control mechanisms
Lecture 1: Mitochondrial quality control- a matter of life and death for neurons
Lecture 2: Mechanisms of mitophagy in Parkinson’s disease
Lecture 3: Mitochondrial remodeling in the control of apoptosis
Parallel Session: Ways for people with Parkinson’s to become empowered
Lecture 1: Why and how people with Parkinson’s need empowerment - Finding your own niche
Lecture 2: Evidence-based self-management practices
Lecture 3: Increasing Parkinson’s advocacy effectiveness with lessons learned from other diseases
Day 2 Parallel Session I
Workshop 1: Benefits and risks of genetic testing
Workshop 2: Sleep and fatigue in PD
Workshop 3: Ethical dilemmas posed by new diagnostic and therapeutic technologies
Workshop 4: Tricks of the trade: clever strategies to improve mobility
L1
Mo
Simon
Werner X
L2
X
L3
X
L1
X
L2
L3
L1
X
L2
L3
X
L1
L2
L3
X
X
X
W1 W2 W3 W4
X
Day 2 Parallel Session II
Parallel Session: PD or look-alikes: how to diagnose them and what are their long-term prognoses?
Lecture 1: Drug Induced Parkinsonism
Lecture 2: PD or progressive supranuclear palsy
Lecture 3: PD or Multiple system atrophy
Parallel Session: Clinical trial outcomes—What do they really mean?
Lecture 1: Clinical trial endpoints in PD – What is really meaningful?
Lecture 2: The placebo effect: how it complicates clinical trial results
Lecture 3: Slowing clinical progression in PD –can it be proven in clinical trials?
Parallel Session: The search for new delivery methods for drugs
Lecture 1: Improving oral drug delivery in PD – recent advances
Lecture 2: Infusion therapies and other non-oral routes of drug delivery
Lecture 3: Delivering therapeutic genes into the brain – a future way of drug delivery?
Parallel Session: Is PD an axonopathy?
Lecture 1: Pathological evidence for axonopathy in Parkinson’s disease
Lecture 2: Evidence for synaptic dysfunction in Parkinson’s disease
Lecture 3: Alterations in axonal transport in Parkinson’s disease
Day 2 Parallel Session II
Workshop: Choosing a care facility: When is it time? What are the options?
Workshop: Do experimental models of Parkinson’s disease predict treatment outcome?
Workshop: Complementary and integrative medicine
Workshop: Dance and Parkinson’s: Why and How?
L1
Mo
Simon
Werner X
L2
X
L3
X
L1
L2
L3
X
X
X
L1
L2
L3
L1
L2
L3
W1 W2 W3 W4
X
X
Day 3 Parallel Session I
Parallel Session: Update on Gaucher and Parkinson's diseases
Lecture 1: What is new about the link between Gaucher mutations and Parkinsonism
Lecture 2: Exploring mechanisms that underlie between mutations in Gaucher disease gene
and synucleinopathy risk
Lecture 3: How the understanding of Gaucher could lead to new therapies for Parkinson's
Parallel Session: New insights into Parkinson's disease from experimental cell- and
gene-based strategies
Lecture 1: Use of human ES and iPS cells for cell replacement in Parkinson´s disease
Lecture 2: Role of Sonic hedgehog in maintaining striatal homeostasis
Lecture 3: Nurr1 as a therapeutic target for neuroprotection and disease modification in PD
Parallel Session: Neurobiology and treatment of dyskinesias
Lecture 1: Maladaptive plasticity in L-DOPA-induced dyskinesia: emerging role of serotonin
transmission and other presynaptic factors
Lecture 2: Pre- and post-synaptic molecular mechanism underlying L-DOPA-induced dyskinesia
possible new pharmacological targets
Lecture 3: Multiple dopamine-dependent synaptic mechanisms underlying dyskinesia in
animal models
Parallel Session: Pathophysiology and management of head drop and bent spine in PD:
Are they dystonia or myopathy or both?
Lecture 1: Myopathy causing camptocormia in idiopathic Parkinson's disease
Lecture 2: Camptocormia: pathogenesis, classification, and response to therapy
Lecture 3: Dropped head syndrome in Parkinson's disease
Day 3 Parallel Session I
Workshop 1: What you need to know about DBS: Selection, side effects, and new device
development
Workshop 2: Is PD an accelerated form of aging?
Workshop 3: Pain in PD
Workshop 4: Speech and Parkinson’s
L1
Mo
Simon
Werner
L2
L3
L1
L2
L3
L1
X
L2
X
L3
X
L1
L2
L3
W1 W2 W3 W4
X
X
X
X
X
Day 3 Parallel Session II
Parallel Session: Freezing and falls
Lecture 1: Freezing- Underlying mechanisms and the role of cueing
Lecture 2: Why do persons with PD fall? Does treatment help to reduce falling?
Lecture 3: The benefits of exercise in reducing falling in PD
Parallel Session: Promising approaches to identify and validate biomarkers
Lecture 1: What are biomarkers and why do we need them?
Lecture 2: Update on unbiased methodologies to identify biomarkers
Lecture 3: Emerging biomarkers
Parallel Session: Drug development challenges: from the pharmaceutical industry,
regulatory agencies, and patient protection organizations perspective
Lecture 1: Drug development challenges-Pharmaceutical industry perspective
Lecture 2: Drug development challenges - A regulatory perspective
Lecture 3: Drug development challenges-Patient protection agency perspective
Parallel Session: How should levodopa induced dyskinesia be managed today?
Lecture 1: Recognizing the subtypes and assessing severity of dyskinesia and the clinical impact
Lecture 2: Current management of LID – medical and surgical
Lecture 3: Future Management of LID: What’s in the pipeline?
Day 3 Parallel Session II
Workshop 1: The role of people with Parkinson's in the research process:
How are they prepared and what can they do?
Workshop 2: Which physical and mental exercises are good for people with Parkinson’s?
Workshop 3: Parkinson's and Mood Changes: Depression, Apathy and Anxiety
L1 L2 L3 L1 L2 L3 L1 L2 L3 L1 L2 L3 W1 W2 W3
Mo
X X X
X
Simon
X
X
Werner
X X X
X